<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="/images/favicon.png" type="image/x-icon">
  <title></title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr.
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterðŸ’œ</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>

    <h1>Cytology in Gynecology with Emphasis on Screening Procedure</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <label class="trigger outline">
        <input type="checkbox" class="checkbox checkbox--red" /> Show/hide outline
        <div class="msg">
         <ol>
            <li><a href="#header-1">Introduction</a></li>
            <li><a href="#header-2">Risk Factors for Cervical Cancer</a></li>
            <li><a href="#header-3">Cervical cancer screening schedule</a></li>
            <li><a href="#header-4">Pap smear</a></li>
            <ul>
              <li><a href="#heading-4-1">Equipment</a></li>
              <li><a href="#heading-4-2">Pre-procedure caution</a></li>
              <li><a href="#heading-4-3">Procedure</a></li>
              <li><a href="#heading-4-4">Bethesda classification</a></li>

            </ul>
            <li><a href="#header-5">Liquid-based Cytology (LBC)</a></li>
            <li><a href="#header-6">Follow Up</a></li>
         </ol>
        </div>
      </label>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Cytology involves observing cells sample under a microscope in order to screen for a cancer or lesions that may develop into cancer.</li>
              <li>Gynecological cytology, also known as PAP test, involves observing a cervical sample under a microscope in order to screen for a cancer or lesions that may develop into cervical cancer.</li>
              <li>Cervical cancer is the third most common malignancy in women worldwide. </li>
              <li>The frequency varies considerably between developed and developing countries</li>
              <li> Cervical cancer is the second most common cancer in developing countries, but only the tenth most common in developed countries. Similarly, cervical cancer is the second most common cause of cancer-related deaths in women in developing countries but is not even among the top 10 causes in developed countries</li>
              <li>Cervical cancer is the most common gynecological cancer in the developing countries and itâ€™s responsible for the most gynecological cancer related deaths in the developing countries</li>
              <li>In the United States, cervical cancer is relatively uncommon.  This trend has been attributed to mass screening with Pap tests.  Cervical cancer rates continue to rise in many developing countries, however.</li>
            </ul>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Risk Factors for Cervical Cancer</a>
          </h2>
        </header>
        <div class='body'>
           <ul>
            <li>Early intercourse/ coitache</li>
            <li>Early marriage</li>
            <li>Multiple child births</li>
            <li>Multiple sexual partners</li>
            <li>Human papilloma virus infection</li>
            <li>Women who are immunosuppressed (HIV positive) </li>
            <li>Smoking habits</li>
            <li>Oral pill users</li>
            <li>There is low risk of cervical cancer developing in fundamental religious groups e.g. Nuns, Amish, Jews, Muslims, it is rare in virgins</li>
           </ul>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Cervical cancer screening schedule</a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li>Intervals: All sexually active women should be screened starting from the age of 21 years or after 3 years of vaginal sex</li>
            <li>Screening should be every 3year (Pap smear only) OR every 5year (for HPV or pap smear/HPV co testing.</li>
            <li>Screening should be done till the age 65years, if the consecutive smears in the last 10 years is negative</li>
            <li>Age 21â€’24: No screening/before pap smear every 3years</li>
            <li>Age 25â€’29: HPV test every 5 years (preferred), HPV/Pap cotest every 5 years (acceptable),Pap test every 3 years (acceptable)</li>
            <li>Age 30â€’65: HPV test every 5 years (preferred), HPV/Pap cotest every 5 years (acceptable),Pap test every 3 years (acceptable)</li>
            <li>Age 65 and older: No screening if a series (3)of prior tests were normal</li>
            <li>Women who are receiving immune suppression therapy; women who are infected with HIV; or women who were exposed to diethylstilbestrol (DES) in utero, should continue to be screened annually. </li>
            <li>Women who are HIV positive should have cervical cytology testing every 6 months after diagnosis, and then annually after 2 consecutive normal test results</li>
          </ul>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Pap smear</a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li>This is the mainstay of cervical cancer screening</li>
            <li>Exfoliated cells from the transformation zone or squamocolumnar junction are obtained for cytology</li>
            <li>Benefits: The objective of screening is to reduce the incidence and mortality from cervical cancer. This achieved through early detection of premalignant lesion </li>
            <li>Pap smear test has been effective reducing the incidence of cervical cancer by 80% and the mortality by 70%. </li>
            <li>As a result of Pap test, more and more preinvasive carcinoma is detected</li>
          </ul>
          <section id='heading-4-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-1'>Equipments</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Examining table with foot support</li>
                <li>Examining light</li>
                <li>Bivalve/cuscos speculum</li>
                <li>Cytobrush </li>
                <li>Glass slides</li>
                <li>Ayre spatula</li>
                <li>Fixative</li>
               </ul>
            </div>
          </section>

          <section id='heading-4-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-2'>Preprocedure caution</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Should be done outside menses</li>
                <li>The woman should avoid intercourse, douching for 24 to 48hour prior to the procedure</li>
                <li>Treat any preexisting infection before the procedure</li>
               </ul>
            </div>
          </section>

          <section id='heading-4-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-3'>Procedure</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>The speculum is placed in the vagina after it has been lubricated with water only.</li>
                <li>With the cervix exposed using bivalve speculum a specially designed plastic or wooden spatula is applied to the cervix and rotated 360 degrees to abrade the surface slightly and to pick up cells from the squamocolumnar area of the cervical os. </li>
                <li>Next, a cotton-tipped applicator or a small brush (cytobrush) is inserted into the endocervix and rotated 360 degrees. </li>
                <li>These 2 specimens can be mixed or placed on the slide separately according to the preference of the examiner. </li>
                <li>A preservative (95% alcohol) is applied immediately to prevent air drying, which would compromise the interpretation. </li>
                <li>The slide is sent to the laboratory with an identification sheet (cytology form) containing pertinent history and finding</li>
               </ul>
            </div>
          </section>

          <section id='heading-4-4'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-4'>Bethesda classification</a>
              </h3>
            </header>
            <div class='body'>
               <p> Reporting of Pap smear is done using Bethesda classification: adequacy of sample is either satisfactory or unsatisfactory</p>
               <h4>Squamous Cell Abnormality</h4>
               <ol>
                <li>Atypical squamous cells (ASC)</li>
                <li>ASC of undetermined significance (ASC-US)</li>
                <li>ASC, cannot exclude high grade lesion (ASC-H)</li>
                <li>Low-grade squamous intraepithelial lesion (L SIL)</li>
                <li>High-grade squamous intraepithelial lesion (H SIL)</li>
                <li>Squamous cell carcinoma</li>
               </ol>

               <h4>Glandular Cells Abnormalities</h4>
               <ol>
                <li>Atypical glandular cells, specify site of origin, if possible</li>
                <li>Atypical glandular cells, favor neoplastic</li>
                <li>Adenocarcinoma in situ</li>
                <li>Adenocarcinoma</li>
               </ol>
            </div>
          </section>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Liquid-based Cytology (LBC)</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Liquid-based Cytology (LBC): Cervical smear is taken using a plastic spatula. The spatula is rinsed in a liquid media.</li>
              <li>Cells are separated by centrifugation. Thin layer smears are made. </li>
              <li>National Institute of Clinical Excellence (NICE) has recommended to replace the conventional smear with LBC. </li>
              <li>LBC avoids the risk of false-positive, false-negative or unsatisfactory smears </li>
            </ul>
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Follow Up</a>
          </h2>
        </header>
        <div class='body'>
           <ul>
            <li>Follow up with result of investigation which is usually according to the Bethesda classification</li>
            <li>Woman with abnormal Pap smear are usually sent for colposcopy</li>
           </ul>
        </div>
      </section>



      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <!-- <p>Send us a <a href="mailto:obgyn.materia@gmail.com"><span class="special-text-2">mail</span></a> at 
         <br> obgyn.materia@gmail.com.</p>
        <p>Or send your comments, corrections, explanations/clarifications and requests/suggestions to our 
         <br> <a href="" class="special-text-2" style="text-decoration: none;">WhatsApp group</a>.</p> -->
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p></p>
          
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="/main.js"></script>
</body>
</html>
 
